文献速递淋巴瘤

通过TBL1X靶向DNA损伤应答治疗套细胞淋巴瘤

Targeting the DNA damage response through TBL1X in mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

套细胞淋巴瘤(MCL)存在显著基因组不稳定且靶向治疗后进展者生存期短,亟需新策略。研究显示MCL细胞高表达TBL1X,基因敲低或使用靶向TBL1X的小分子tegavivint可促进MCL细胞在体内外死亡;TBL1X调控cyclin D1和RAD51稳定性,靶向TBL1X导致DNA损伤、细胞周期阻滞和死亡;tegavivint与talazoparib联用在体外协同诱导MCL细胞死亡,在体内显著延长患者来源MCL异种移植模型生存。

要点

  • MCL细胞较正常B细胞高表达TBL1X,其参与维持基因组稳定性。
  • 靶向TBL1X导致DNA损伤、细胞周期阻滞并最终引起MCL细胞死亡。
  • tegavivint联合talazoparib在体外协同诱导MCL细胞死亡,在体内延长患者来源MCL异种移植生存。

核心结论

  • 结果界定TBL1X在维持MCL基因组稳定性中的作用,并将靶向TBL1X确立为这种不可治愈疾病患者的新治疗策略。

研究设计与样本

  • 研究在体外和体内比较MCL细胞与正常B细胞的TBL1X表达,并采用基因敲低和TBL1X靶向小分子tegavivint处理,评估MCL细胞死亡。

主要发现

  • 与正常B细胞不同,MCL细胞表达高水平TBL1X。
  • 基因敲低TBL1X和tegavivint处理在体外和体内均促进MCL细胞死亡。
  • TBL1X调控关键MCL致癌驱动因子cyclin D1和RAD51的稳定性。
  • 靶向TBL1X导致显著DNA损伤、细胞周期阻滞并最终细胞死亡。
  • tegavivint与talazoparib联用在体外协同诱导MCL细胞死亡,在体内显著延长患者来源MCL异种移植的生存。

临床怎么用

  • 作者认为靶向TBL1X是MCL患者的新治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma characterized by significant genomic instability. Patients with MCL who progress on targeted therapies have a short survival; thus, novel therapeutic strategies are urgently needed. Overexpression of transducin β-like protein 1 X-linked (TBL1X) has been documented in several types of cancer and associated with poor prognosis. TBL1X is a critical regulator of multiple oncogenic networks; however, its function in MCL has not been explored. Our data show that, unlike normal B cells, MCL cells express abundant levels of TBL1X and that genetic knockdown of TBL1X and treatment with tegavivint (Iterion), a first-in-class small molecule targeting TBL1X, promote MCL cell death in vitro and in vivo. Moreover, TBL1X controls the stability of key MCL oncogenic drivers, cyclin D1 and RAD51; and targeting TBL1X results in significant DNA damage, cell cycle arrest, and ultimately cell death. Combining tegavivint with poly(adenosine 5'-diphosphate-ribose) polymerase-1/2 inhibitor talazoparib results in synergistic MCL cell death in vitro, and in vivo this combination significantly prolongs the survival of a patient-derived MCL xenograft. Together, our results define the role of TBL1X in maintaining genomic stability in MCL and establish targeting TBL1X as a novel therapeutic strategy for patients with this incurable disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pray B, Baiocchi E, Leon S, et al. Targeting the DNA damage response through TBL1X in mantle cell lymphoma. Blood Adv. 2025. PMID: 40009753. doi:10.1182/bloodadvances.2024015769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。